Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Leticia Ussem, Karin U. Loeffler, Verena Tischler, Marieta Toma, Natalie Pelusi, Frank G. Holz, Anne Gulbins, Daniela Süsskind, Martina C. Herwig-Carl
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Uveal melanoma: comprehensive review of its pathophysiology, diagnosis, treatment, and future perspectives
10.3390/biomedicines12081758 · 2024
Advances in the clinical management of uveal melanoma
10.1038/s41571-022-00714-1 · 2023
GNAQ and GNA11 mutations in uveal melanoma
10.1097/cmr.0000000000000121 · 2014
GNAQ and GNA11 genes: a comprehensive review on oncogenesis, prognosis and therapeutic opportunities in uveal melanoma
10.3390/cancers14133066 · 2022
Prognostic implications of monosomy 3 in uveal melanoma
10.1016/s0140-6736(96)90736-9 · 1996
Driver mutations in uveal melanoma associations with gene expression profile and patient outcomes
10.1001/jamaophthalmol.2016.0903 · 2016
Prognostic parameters in uveal melanoma and their association with BAP1 expression
10.1136/bjophthalmol-2014-305047 · 2014
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
10.1038/ng.2674 · 2013
Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases
10.1016/j.ophtha.2016.01.023 · 2016
Uveal melanoma: towards a molecular understanding
10.1016/j.preteyeres.2019.100800 · 2020
Mass spectrometry-based profiling of histone post-translational modifications in uveal melanoma tissues, human melanocytes, and uveal melanoma cell lines—a pilot study
10.1167/iovs.65.2.27 · 2024
Spatial intratumor heterogeneity in uveal melanoma: tumor cell subtypes with a presumed invasive potential exhibit a particular epigenetic staining reaction
10.1016/j.exer.2019.04.001 · 2019
Integrative analysis identifies four molecular and clinical subsets in uveal melanoma
10.1016/j.ccell.2017.07.003 · 2017
Genome-wide aberrant methylation in primary metastatic UM and their matched metastases
10.1038/s41598-021-03964-8 · 2022
How to make immunotherapy an effective therapeutic choice for uveal melanoma
10.3390/cancers13092043 · 2021
Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges
10.1111/febs.15707 · 2022
Identification of targetable epigenetic vulnerabilities for uveal melanoma
10.1038/s41419-025-08295-4 · 2025
Histone deacetylase (HDAC) inhibitors: a promising weapon to tackle therapy resistance in melanoma
10.3390/ijms23073660 · 2022
Novel uveal melanoma patient-derived organoid models recapitulate human disease to support translational research
10.1167/iovs.65.13.60 · 2024
Patient-derived organoids in precision cancer medicine
10.1016/j.medj.2024.08.010 · 2024
Organoid modeling of the tumor immune microenvironment
10.1016/j.cell.2018.11.021 · 2018
Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy
10.3389/fonc.2020.01775 · 2020
Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation
10.1007/s13402-025-01158-2 · 2026
Reconstituting the head and neck tumor microenvironment with air-liquid interface organoids
10.3389/fonc.2025.1736505 · 2025
Preparation of human primary colon tissue-derived organoid using air liquid interface culture
10.1002/cptx.40 · 2018
Colorectal air-liquid interface organoids preserve tumour-immune architecture and reveal local Treg expansion after PD-1 blockade
10.3390/cancers18010132 · 2025
PANTHER: making genome-scale phylogenetics accessible to all
10.1002/pro.4218 · 2022
PANTHER pathway: an ontology-based pathway database coupled with data analysis tools
10.1007/978-1-60761-175-2 · 2009
Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0)
10.1038/s41596-019-0128-8 · 2019
Enrichment of histones from patient samples for mass spectrometry-based analysis of post-translational modifications
10.1016/j.ymeth.2019.10.001 · 2020
A super-SILAC approach for profiling histone posttranslational modifications
10.1007/978-1-0716-2863-8 · 2023
Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
10.1186/s13148-021-01120-7 · 2021
ProteomeXchange provides globally coordinated proteomics data submission and dissemination
10.1038/nbt.2839 · 2014
Extensive and systematic rewiring of histone post-translational modifications in cancer model systems
10.1093/nar/gky224 · 2018
Ribonucleotide reductase M2 (RRM2): regulation, function and targeting strategy in human cancer
10.1016/j.gendis.2022.11.022 · 2024
Genetic and molecular characterization of uveal melanoma cell lines
10.1111/j.1755-148x.2012.00971.x · 2012
Animal models of uveal melanoma
10.21037/aes-21-30 · 2022
Pathology tissue-quantitative mass spectrometry analysis to profile histone post-translational modification patterns in patient samples
10.1074/mcp.m115.054510 · 2016
Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma
10.1158/1541-7786.mcr-20-0434 · 2021
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma
10.1158/1078-0432.ccr-11-0946 · 2012
HDAC inhibition increases HLA class I expression in uveal melanoma
10.3390/cancers12123690 · doi-reference
Uveal melanoma cell line proliferation is inhibited by ricolinostat, a histone deacetylase inhibitor
10.3390/cancers14030782 · doi-reference